Information on Gemini Therapeutics, including GEM103 and initial ReGAtta data, and the e-poster presented at AAO 2021, can be found on Gemini Therapeutics’ website under the Investors & Media ...

In June 2021, Gemini shared initial data from its ongoing ReGAtta study, an open-label Phase 2a trial of its lead product candidate, GEM103, in patients with GA secondary to dry AMD.